on TRANSGENE (EPA:TNG)
Transgene to Present VacDesignR® Tool at ESMO AI 2025
Transgene, a biotech company focused on designing virus-based cancer therapies, announced it will showcase its VacDesignR® computational tool at the ESMO AI & Digital Oncology 2025 conference in Berlin. This tool improves the design and efficiency of recombinant Modified Vaccinia Ankara (MVA)-based vectors. It supports the production of individualized neoantigen therapeutic vaccines (INTV), currently under clinical trial.
VacDesignR® optimizes recombinant plasmid architecture for MVA vectors, enhancing production reliability. Future updates will integrate AI components to boost performance and scalability, aligning with Transgene's strategic goals. The tool aids in developing individualized vaccines such as TG4050 for HPV-negative head and neck cancers.
The presentation includes a poster entitled “VacDesignR®: a tool for optimizing recombinant poxvirus vaccine production,” at the ESMO-AI conference on November 12, 2025.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TRANSGENE news